NASDAQ:SEPN

Septerna Q4 2025 Earnings Results & Report

Septerna logo
$41.67 -0.93 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.02 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna missed analyst earnings expectations in its Q4 2025 results, released March 9, 2026. The company reported EPS of -$0.24 versus the -$0.23 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Septerna EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Septerna Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.44 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Septerna Q4 2025 Earnings FAQ

Septerna (NASDAQ:SEPN) reported earnings of -$0.24 per share for Q4 2025, missing the consensus estimate of -$0.23. The report was announced on Monday, March 9, 2026.

Septerna Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Septerna (NASDAQ:SEPN) Director Sells $3,934,723.80 in Stock
Septerna FY2026 Earnings Forecast Lowered by HC Wainwright
Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development. The company has also pursued collaborations to apply its GPCR discovery capabilities to additional therapeutic programs.

View Septerna Profile